| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SETD7 |
| Uniprot No | Q8WTS6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-366aa |
| 氨基酸序列 | MDSDDEMVEEAVEGHLDDDGLPHGFCTVTYSSTDRFEGNFVHGEKNGRGK FFFFDGSTLEGYYVDDALQGQGVYTYEDGGVLQGTYVDGELNGPAQEYDT DGRLIFKGQYKDNIRHGVCWIYYPDGGSLVGEVNEDGEMTGEKIAYVYPD ERTALYGKFIDGEMIEGKLATLMSTEEGRPHFELMPGNSVYHFDKSTSSC ISTNALLPDPYESERVYVAESLISSAGEGLFSKVAVGPNTVMSFYNGVRI THQEVDSRDWALNGNTLSLDEETVIDVPEPYNHVSKYCASLGHKANHSFT PNCIYDMFVHPRFGPIKCIRTLRAVEADEELTVAYGYDHSPPGKSGPEAP EWYQVELKAFQATQQK |
| 预测分子量 | 75 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SETD7重组蛋白的3篇参考文献概览(注：以下内容为模拟示例，实际文献需通过学术数据库查询)：
---
1. **文献名称**：*Structural Basis for Substrate Specificity of SET Domain Protein Methyltransferases*
**作者**：Zhang, X. et al.
**摘要**：该研究解析了SETD7重组蛋白的晶体结构，揭示其催化结构域如何识别组蛋白H3的N端序列，并阐明了单甲基化转移酶活性的分子机制。
---
2. **文献名称**：*Recombinant SETD7 Expression and Characterization of Its Methyltransferase Activity In Vitro*
**作者**：Patel, A. & Cheng, D.
**摘要**：通过大肠杆菌表达系统成功纯化重组SETD7蛋白，体外实验证实其对组蛋白H3K4的单甲基化功能，并发现其活性受SAM(S-腺苷甲硫氨酸)浓度的调控。
---
3. **文献名称**：*SETD7-Mediated Non-Histone Methylation in Diabetic Complications*
**作者**：Li, Y. et al.
**摘要**：利用重组SETD7蛋白探究其对非组蛋白底物(如p53)的甲基化作用，发现其在糖尿病相关炎症通路中的调控功能，为疾病治疗提供潜在靶点。
---
如需具体文献，建议通过PubMed或Google Scholar搜索关键词“SETD7 recombinant protein”或“SETD7 methyltransferase activity”获取最新研究。
SETD7 (SET Domain-Containing Protein 7), also known as SET7/9 or KMT7. is a member of the protein lysine methyltransferase (PKMT) family. It is characterized by a conserved catalytic SET (Su(var), E(z), and Trithorax) domain, which facilitates the transfer of methyl groups to specific lysine residues on substrate proteins. Unlike many methyltransferases that target histones, SETD7 primarily catalyzes monomethylation of histone H3 at lysine 4 (H3K4me1), a modification associated with transcriptional activation. Additionally, SETD7 methylates non-histone proteins, including transcription factors (e.g., p53. ERα, NF-κB) and signaling molecules (e.g., DNMT1. EZH2), thereby regulating their stability, localization, or activity. This dual substrate specificity positions SETD7 as a key player in gene expression, cell cycle progression, differentiation, and stress responses.
Recombinant SETD7 protein is engineered for in vitro studies to dissect its enzymatic mechanisms, substrate interactions, and regulatory roles. Produced via heterologous expression systems (e.g., E. coli or mammalian cells), the purified protein retains methyltransferase activity and structural integrity. Its applications span enzymatic assays, crystallography, and inhibitor screening, particularly in cancer research, where aberrant SETD7 activity is linked to tumor suppression or progression depending on context. Dysregulation of SETD7 has also been implicated in metabolic disorders and cardiovascular diseases, making it a potential therapeutic target. Recombinant SETD7 tools are vital for advancing epigenetic and post-translational modification research, offering insights into disease pathways and drug discovery.
×
